SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

<u>Drug Requested</u>: **Sucraid**[®] (sacrosidase)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.		
Member Name:		
Member Sentara #:		
Prescriber Name:		
Prescriber Signature:		
Office Contact Name:		
Phone Number:	Fax Number:	
DEA OR NPI #:		
DRUG INFORMATION: Authorization may be	delayed if incomplete.	
Drug Form/Strength:		
Dosing Schedule:	Length of Therapy:	
Diagnosis:	ICD Code, if applicable:	
Weight:	Date:	
Quantity Limit: 236mL/30 days		
CLINICAL CRITERIA: Check below all that ap support each line checked, all documentation, including provided or request may be denied.		
Initial Approval : 60 days		
Patient is 5 months of age or older and has a diagnosis of congenital sucrase-isomaltase deficiency (CSID) confirmed by a gastroenterologist, endocrinologist, or genetics specialist		
AND		
☐ Patient has documented chronic symptoms of CS gas/bloating after sucrose/starch ingestion (must sucrose/starch ingestion)	ID including watery diarrhea, abdominal pain, submit chart notes documenting symptoms following	
• Number of severe GI events within the last 2 submitted chart notes)	months: (must be documented in	
AND		

(Continued on next page)

	A low sucrose and low starch diet has been attempted with improvement in patient symptoms, and patient will continue to follow a low sucrose, low starch diet while on therapy	
	AND	
	Patient does not have lactose intolerance or a secondary sucrase deficiency associated with any of the following: celiac disease, Crohn's disease, autoimmune gastroenteropathy, eosinophilic gastroenteropathy, short bowel syndrome, Giardiasis, small intestinal bacterial overgrowth (SIBO), acute gastroenteritis, or enteropathy associated with acquired immune deficiency syndrome	
AND (ALL 4 below MUST be met):		
	□ Stool pH < 6.0	☐ Increase in breath hydrogen of > 10 ppm when challenged with sucrose after fasting
	☐ Genetic test results confirm diagnosis of CSID	☐ Negative lactose breath test
	<u>OR</u> (<u>BOTH</u> below <u>M</u>	IUST be met)
□ Small bowel biopsy documents intestinal sucrase activity of <25 U/g protein (must be greater than 2 standard deviations below the mean) with normal or decreased maltase and isomaltase levels, normal levels of other disaccharides, and normal villous architecture of the small intestine on biopsy		
	Genetic testing results document sucrase-isoma	ltase deficiency (CSID)
ppro		eck below all that apply. All criteria must be met for ration, including lab results, diagnostics, and/or chart
	Patient has had a 50% reduction in all symptom gas/bloating; etc. (improvement from baseline) • Number of severe GI events within the last	
	submitted chart notes)	
	AND	
	Patient will continue to follow a low sucrose, lo	w starch diet while on therapy.
Med	ication being provided by Specialty Ph	armacy - PropriumRx
		· · ·

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

**Use of samples to initiate therapy does not meet step edit/preauthorization criteria. **

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.